In the context of drug repurposing, the myelin-promoting properties of donepezil, along with its dual inhibitory activity against AChE and activation of Sig-1R, render it as a promising candidate for the management of demyelinating diseases. The gene discussed is SIGMAR1; the disease is demyelinating disease.